Biocon Biologics is a fully-integrated pure-play biosimilars organization globally engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to cutting-edge therapies. It develops and commercializes a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe. The company is driven by a belief that the pharmaceutical industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.